
|Articles|November 20, 2007
Oral drug approved to treat liver cancer
Nexavar gains new indication approval for liver cancer
Advertisement
Nexavar (sorafenib) tablets, originally approved to treat advanced kidney cancer, have just been approved for a new indication. The kinase inhibitor can now be used to treat liver cancer as well. The oral anticancer drug, a product of Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, was approved on a priority review basis. According to Bayer, sorafenib is the first approved systemic therapy for liver cancer and the only one shown to significantly improve survival.
To go to the Drug Topics homepage,
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Model Finds Weight Regain After Stopping Semaglutide or Tirzepatide
2
Study Identifies Patients at Risk for Severe COVID-19 Post-Vaccination
3
Investigational Oral AD109 Reduces Sleep Apnea Severity by 44%
4
Zepbound Lowers Health Care Costs in Older Adults With Obesity
5







































